Objective: To determine the cost-effectiveness of initiation of second-line hormone therapy with letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada, compared to megestrol acetate. Methods: A modified Markov model, incorporating seven health states, was designed to simulate the treatment of patients with advanced breast cancer from second-line hormone therapy to death. The model was constructed with data from a clinical trial, literature sources, and interviews with breast cancer treatment experts. Canadian experts provided information on resource utilization patterns and local costs were attached to these resources. The model was used to calculate mean survival time, time without progression, and total direct medical costs for patients initiating treatment with letrozole 2.5 mg or megestrol acetate 160 mg. Results: The mean survival time and time without progression for letrozole 2.5 mg patients were 28.3 months and 19.0 months, respectively, compared to 25.7 months and 16.5 months for megestrol acetate 160 mg patients. Total treatment costs for both groups were similar with the letrozole 2.5 mg group costing $20,068 per patient, $1061 more than the megestrol acetate 160 mg group ($CAN, 1996). The cost-effectiveness ratio for letrozole 2.5 mg with respect to megestrol was $5051 per year of life gained. Sensitivity analysis showed that this ratio was sensitive to variations in the probabilities governing disease progression. Conclusions: Advanced breast cancer patients initiating second-line hormone therapy with letrozole 2.5 mg have better clinical outcomes than patients receiving megestrol acetate 160 mg. Furthermore, this benefit comes at an acceptable cost to the Canadian health care system.
Introduction
Breast cancer is the most common malignancy among women in the developed world, and the worldwide burden of the disease continues to increase [1, 2] . In 1998 in Canada it was estimated that there would be 19,300 new cases of breast cancer diagnosed with 5,300 deaths [3] . The probability of developing the disease is highly dependent on age, with most of the risk apparent after age 50 [1, 4] . In Canada the overall lifetime probability of developing breast cancer is presently 11% and the risk of dying from the disease is 4.1% [3, 5] .
Although breast cancer is now recognized as a systemic disease there is a marked heterogeneity in progression of the disease [6] ; treatment options are dictated by the size and hormonal status of the tumor and the presence or absence of metastatic cancer [7] [8] [9] [10] [11] [12] . Patients presenting with locally advanced or metastatic breast cancer, or those who develop metastatic disease after initial treatment, have a high incidence of recurrence [13] . On recurrence, patients are usually treated with a second-line therapy consisting either of chemotherapy or hormonal therapy. The decision as to the choice of second-line therapy depends on the firstline therapy employed and the response of the tumor to this initial therapy [4, [14] [15] [16] .
The overall economic impact of breast cancer is difficult to assess because of the wide variation in patient response, the long-term course of disease in some patients, and different therapeutic approaches. Nevertheless, several studies have attempted to evaluate the cost of treating the disease [11, 12, 17, 18] and the cost-effectiveness of screening programs designed to identify breast cancer patients at an early stage of the disease [19] . In a study on advanced breast cancer patients in The Netherlands, de Koning et al. [20] calculated the lifetime treatment costs in 1990 at NLG 34, 200 ($24,618 CAN) which increased to NLG 42,000 ($30,233 CAN) when ambulatory costs were included. The major cost driver in treatment was hospitalization, which was 62% of the total cost while drug costs were only eight percent of the total. Other studies have shown that a major determining factor in the economic burden of advanced breast cancer is the cost associated with treatment of disease recurrence [17] .
Although the clinical value of new therapeutic approaches to the treatment of advanced breast cancer can be demonstrated in clinical trials, it has become increasingly important to health care decision-makers that new therapies are shown to provide cost-effective care. Letrozole is a selective aromatase inhibitor for the second-line management of advanced breast cancer in postmenopausal women and the efficacy of the drug has been demonstrated in a clinical trial [21] . The present study examines how the introduction of this drug would impact the overall treatment costs associated with the long-term management of advanced breast cancer patients in Canada. In the absence of prospective health economic data, the study relies on decision analytical modeling to project long-term clinical and economic consequences.
Methods

Design
A semi-Markov process model was constructed to simulate the course of advanced breast cancer in a typical patient treated either with letrozole or megestrol acetate as a second-line hormone therapy [22] . The foundation of the model was data from a clinical trial and the patient population defined for the model was identical to the patients recruited for this trial [21] . These patients were postmenopausal women with advanced breast cancer who had previously failed first-line antiestrogen or adjuvant antiestrogen therapy and, at the time of recruitment, had no rapidly progressive disease. The analysis covered the period between the initiation of second-line therapy and death (lifetime model). The effectiveness of treatment was expressed as survival and time without progression and the model incorporated all relevant economic measures. These included direct medical resource utilization patterns associated with outpatient and inpatient care for the treatment of advanced breast cancer. Indirect resources and costs were not assessed. In the primary analysis costs were discounted at 5% annually while outcomes were not discounted and the perspective of the economic assessment was that of the thirdparty payer in Canada (the provincial Ministries of Health).
Model
This model has already been described in detail by Nuijten et al. [23] . In brief, a computer software package (DATA2.6, TreeAge) was used to create the Markov model, which was designed to incorporate seven primary health states: second-line hormone treatment, third-line hormone treatment, chemotherapy 1, chemotherapy 2, observational care, end-stage palliative care, and death. The model simulated lifetime outcomes for patients presenting with advanced breast cancer, where the time period was broken down into cycles of 3 months. This cycle time was chosen because in the clinical trial patients were assessed at 3-month intervals. The maximum follow-up period of the model was based on a cut-off point where less than 1% of the patients would still be alive.
Patients entering the model were randomly assigned second-line hormone therapy with either letrozole 2.5 mg or megestrol acetate 160 mg. At the end of the first cycle this therapy was assumed to lead to one of four clinical outcomes: 1) no progression with severe adverse events; 2) no progression without severe adverse events; 3) progression with severe adverse events; or 4) progression without severe adverse events. In the absence of progression and adverse events, the patient would likely continue to receive the same second-line hormone therapy. However, for the remaining clinical outcomes a patient would either continue on second-line hormone therapy or alternatively receive a change in treatment. The possible changes in treatment are shown in Figure 1 , which defines the structure of the letrozole arm of the Markov model for this first cycle. The probability of a particular outcome and the probabilities defining which treatment the patient would receive are based on transition probabilities which are incorporated into the model. Although Figure 1 only shows a small portion of the complete model, subsequent arms of the model develop in the same manner and the movement of a patient through the model is dependent on the presence or absence of disease progression at the end of each cycle. A schematic diagram of the complete model is shown in Figure 2 . The model structure for megestrol acetate 160 mg is identical to that for letrozole 2.5 mg. The clinical role of adverse events in initiating a treatment change was only incorporated into the second-line hormone health state and the probability of these events occurring was determined directly from the clinical trial data (see below) [21] . In succeeding health states adverse events were not directly incorporated into the model since the occurrence of these events could not be determined with any degree of accuracy from the data sources.
Data Collection
For the probabilities of clinical outcomes and occurrence of adverse events during second-line hormone therapy, data were derived directly from the clinical trial [21] . A retrospective analysis was used because the model was developed while the clinical trial was ongoing. An intent-to-treat ap- proach was employed to calculate the probability of patients experiencing disease progression, a treatment related severe adverse event, discontinuing second-line therapy as well as the reason for discontinuation, and the percentage of patients dying in each 3-month period. For the letrozole patients, only those receiving 2.5 mg daily, as distinct from those receiving 0.5 mg in the clinical trial, were used for the analysis, because this was the most effective dose [21] . Clinical data relating to the second-line hormone health state in the model are shown in Table 1 .
Beyond second-line hormone therapy, information on transition probabilities and treatment alternatives was obtained from the literature and by expert interview. This information is summarized in Table 1 and described in detail by Nuijten et al. [23] . For each health state published data from randomized clinical trials were used to derive the probability of having a response or a relapse to the particular therapy, as well as the probability of dying as a result of disease progression in the health state. Average weighted values were determined from the appropriate literature where the weighting was based on the number of patients in each clinical trial. Since published trials lasted for different periods of time the actuarial method [24] was used to adjust probabilities to a cycle time of 3 months. For projection of the published clinical data onto the model it was assumed that response rates beyond second-line hormone therapy were independent of the exact therapy used. For example, probabilities for patients in the chemotherapy 1 health state were based on the general response of patients to chemotherapeutic regimens, rather than the response to a specific combination of drugs. Treatment alternatives derived from the literature were validated by six breast cancer experts, two from Holland, three from the United Kingdom, and one from Canada. In addition, a panel of eight Canadian experts validated or modified treatment alternatives and provided missing transition probabilities to reflect treatment practices for advanced breast cancer patients in Canada. These experts were interviewed using the modified Delphi method [25] .
Resource Utilization
Resource utilization patterns were determined by assessing direct medical resources for each health state defined by the model. Resources were identified and quantified by the eight Canadian expert interviews. Among the resources assessed were outpatient care, including drug therapy, consultations (physicians and allied health care workers) and laboratory tests and procedures, and inpatient care, which included hospitalization and physician consultations. Four of the experts provided information on health care utilization associated with the treatment of severe adverse events during second-line hormone therapy.
Costing
A cost for each health state was determined by applying unit costs to the resources associated with each state. All costs were expressed in 1996 Canadian dollars and costing was accomplished using unit prices from the Province of Ontario. The costs for outpatient drugs were obtained either from the Ontario Drug Benefit Formulary/Comparative Drug Index or, for those drugs not listed in the formulary, using case costing data from the Ottawa General Hospital. Outpatient physician consultation fees were obtained from the Ontario Schedule of Benefits, as were the costs for outpatient laboratory tests and procedures, although in this case some costs were also obtained from the 
Cost-Effectiveness Analysis
The model was used to determine incremental cost-effectiveness ratios for the treatment of advanced breast cancer in Canada with letrozole 2.5 mg. To determine the ratios, average per patient treatment costs and the average patient clinical outcomes were determined for both treatment arms by a foldback analysis of the complete model [26] . Incremental cost-effectiveness ratios (CE ratio) were determined in the following manner:
where C L and C M are the total treatment costs for patients who initially received letrozole 2.5 mg or megestrol acetate 160 mg, respectively, and E L and E M the mean survival time or time without progression for the same treatment groups. The ratios were expressed in terms of the cost per year of life gained or the cost per month without progression.
Sensitivity Analyses
Sensitivity analyses were designed to test the stability of the clinical and economic conclusions derived from the model. Significant transition probabilities were varied within the model and subsequent effects on the cost-effectiveness ratios calculated. In particular, probabilities governing progression without an adverse event within 3 months of initial therapy or after 3 months of therapy for both letrozole-and megestrol acetate-treated patients were varied. In both cases the data defining the range for the analysis was based on minimum and maximum probabilities from the clinical trial. The trial data indicated that the probability of progression after 3 months of second-line therapy varied per 3-month cycle. For the primary analysis this probability was assumed to remain constant over time. However, a sensitivity analysis, incorporating ranges defined by the minimum and maximum probabilities of progression per cycle, tested the impact of this variability on the cost-effectiveness ratio. Probabilities for some variables were also varied
between the minimum and maximum values recorded by the different experts. In a second series of analyses, major cost drivers in health states (hospitalization, drugs and adverse events) were varied by Ϯ 20%.
Results
The model constructed for this study simulated the long-term treatment of advanced breast cancer in postmenopausal women in Canada, incorporating 25 cycles, each of a 3-month duration, for a total period of 6.3 years. The 25 cycle, 6.3-year cut-off was chosen because at this point only 1% of the patients were still alive. Table 2 shows the average projected long-term clinical outcomes obtained for each virtual cohort, when the second-line hormone therapy results were incorporated into the model simulating long-term care of these patients. Although the model was designed to cover 6.3 years, mean survival time for patients who initially received letrozole 2.5 mg was 28.26 months, compared to 25.74 months for the megestrol acetate 160 mg patients. The mean time to progression, calculated as a cumulative time over all health states, was 19 months for the letrozole 2.5 mg patients and 16.5 months for those patients initially receiving megestrol acetate 160 mg.
Resource utilization patterns derived from the model are summarized in Table 3 with information for five of the seven health states shown. The results indicate that patients receiving letrozole 2.5 mg in second-line hormone therapy, who subsequently go on to receive third-line hormone therapy, were all assumed to receive megestrol acetate 160 mg in this health state. Physician consultations were common for all patients in each health state but hospitalization was restricted to a small number of patients, except in the end-stage palliative care health state.
An average patient cost for the disease was determined by calculating patient time spent in each health state and applying health state costs to the time spent (Table 4 ). The direct medical costs for both treatment groups were similar with the total cost for the letrozole 2.5 mg patient group slightly higher than that of the megestrol acetate 160 mg patients ($1061 difference). Within both groups the major cost driver was medication which comprised 42% and 38% of the final costs for the letrozole 2.5 mg and megestrol patients, respectively. Hospitalization was the next most significant cost driver (35% of total cost in both treatment groups). Incremental cost-effectiveness ratios were calculated to link the clinical and economic model outcomes. Incremental ratios were expressed in two forms, calculated in both cases for patients taking letrozole 2.5 mg with respect to those taking megestrol acetate 160 mg. When the calculation was based on life-years gained by taking letrozole 2.5 mg (0.3 years increased survival time for patients taking letrozole 2.5 mg, compared to those taking megestrol acetate 160 mg) the costeffectiveness ratio was $5051 per life-year gained. Alternatively, when the incremental ratio was expressed in terms of the time without progression, the ratio was $424.40 per month without progression for the letrozole 2.5 mg population.
Because of the complexity of the model, several sensitivity analyses were carried out to test the robustness of the results. When the cost of hospitalization was varied by Ϯ 20% there was only a 1% variation in the cost-effectiveness ratio (Table 5) . However, when the cost of adverse events was varied by Ϯ 20% the cost-effectiveness ratio for letrozole 2.5 mg varied by Ϯ 7.8%, a reflection of the impact of adverse events on the overall cost of care with megestrol acetate 160 mg. There was only an 8% to 2.6% change in the ratio when che- motherapy costs were varied from their minimum to maximum values (Table 5 ).
In the base case analysis, the probability of having a progression (without a serious adverse event, or SAE) within 3 months of second-line hormone therapy was 0.394 for letrozole 2.5 mg and 0.352 for megestrol acetate 160 mg ( Table 1) . Variation of the probability of progression for letrozole 2.5 mg from 0.321 to 0.468 changed the incremental cost-effectiveness ratio from $4558 to $6163, but treatment with letrozole remained cost-effective compared to megestrol. However, when the probability for progression with megestrol was varied (0.282-0.420) treatment with this drug became clinically and economically dominant over letrozole 2.5 mg at the lowest probability value (0.282). There were also large changes in the cost-effectiveness ratio when the probabilities of progression after 3 months were varied. For letrozole 2.5 mg, when the probability varied from 0.139 to 0.583, the mean patient survival time decreased from 2.8 years to 1.7 years and the cost-effectiveness ratio went from $5506 per life-year gained to a situation where megestrol acetate 160 mg was clinically and economically dominant at the higher probability value. Similarly, when the probability of progression with megestrol acetate after 3 months was varied from 0.600 to 0.318, the incremental cost-effectiveness for letrozole decreased from $2820 to a situation in which megestrol acetate was the more dominant drug.
When the response rates to therapy were increased or decreased in the third-line hormone health state or in either of the two chemotherapy health states, there was little or no subsequent change in the cost-effectiveness ratio for letrozole 2.5 mg (results not shown). Hence the incremental cost-effectiveness ratio for letrozole 2.5 mg was mainly sensitive to efficacy changes in the secondline hormone treatment phase of the disease.
Discussion
In this study clinical and economic outcomes were compared in advanced breast cancer patients initiating second-line hormone therapy with either letrozole 2.5 mg or megestrol acetate 160 mg. The study was not restricted to outcomes during second-line therapy alone but followed patients through subsequent treatment options to eventual death, and as such provides an estimate of the economic burden associated with the treatment of advanced metastatic breast cancer patients in Canada. Modeling studies of this nature have limitations since the results are at best a representation of what might be found in clinical practice.
Limitations are due to a number of factors, including reliance on expert opinion for resource utilization information and the derivation of probabilities for clinical events from published results of clinical trials. Clinical trials have a low external validity and because treatments are protocol driven the clinical results may not reflect actual day-to-day treatment of advanced cancer patients. Nevertheless, a model does provide a mechanism for the determination of longterm average patient outcomes.
Given the drawbacks associated with this type of study design an extensive validation process and sensitivity analysis was performed. The assumptions used to define the main characteristics of the model (model structure/treatment pattern, cycle time, health states, comparator, perspective) and the findings of the study were validated by expert opinion and the literature. The reliability of the model was assessed by comparing the outcomes of the model with existing data from the literature and the updated AR/BC2 clinical trial data. In the most recent follow-up data from the trial (status as of 31 May 1997) patient survival was estimated at approximately 2 years (21-25 months, depending on the treatment arm). In addition, the 2-year survival figures for letrozoleand megestrol acetate-treated patients from the extended AR/BC2 trial were 56% and 46%, respectively, while the model yielded survival rates of 46% and 37%. While there is a substantial difference in the absolute survival values between the real and modeled outcomes, the difference in sur- vival remains essentially the same at approximately 10% for both drugs.
Other studies support the validity of the model. In particular, published values for the median survival time for patients with advanced breast cancer are approximately 2 years [10, 18] . This compares favorably with the mean survival times of 2.1 years for letrozole 2.5 mg and 1.9 years for megestrol acetate 160 mg calculated from the model. The economic outcomes predicted by the model also compare favorably with data in the literature. The total per patient treatment costs determined in this study were $20,068 and $19,007 for patients initially receiving second-line hormone therapy with letrozole 2.5 mg or megestrol acetate 160 mg, respectively. In a retrospective analysis of patient charts in the United Kingdom, Richards et al. [18] calculated the mean per patient cost (£1991) for advanced breast cancer patients at £7620 ($17,146 CAN), close to the figure determined here. In addition, findings have been tested by sensitivity analyses and results compared to other studies. The results of these analyses indicate that clinical efficacy and safety play significant roles in determining the final outcomes of the model. This is consistent with the findings of Hutton et al. [13] who noted that response rate is a key parameter determining the utility of chemotherapy.
On the basis of the model, patients initially receiving letrozole in second-line therapy had a 10% increase in survival and a 15% increase in time to progression. For the latter, cumulatively calculated over the different treatment options, letrozole patients had a mean time without progression of 19 months. Therefore patients receiving letrozole in second-line therapy have improved clinical outcomes compared to patients receiving megestrol.
The cost-effectiveness ratio for letrozole 2.5 mg ($5051 per life-year gained) represents the increased cost to the Ministry of Health for the better clinical outcomes associated with the care of advanced breast cancer patients with letrozole 2.5 mg, compared to their care with megestrol acetate. In general terms, a cost-effectiveness ratio of $5051 is excellent value when compared to other presently funded medical interventions such as renal dialysis where the ratio varies from $20,000 to $74,000 (1993 $US) [27] . In addition, this ratio is highly favorable when compared to other cancer therapies. The cost-effectiveness ratio for postsurgical chemotherapy for premenopausal women with breast cancer is $18,000 (1993 $US) per life-year gained [27] and Covens et al. [28] calculated a ratio of $20,355 (1993, $CAN) per life-year gained for the treatment of advanced ovarian cancer with paclitaxel and cisplatin.
In conclusion, the present study suggests that letrozole 2.5 mg may be a suitable alternative to megestrol acetate 160 mg as second-line hormone therapy in the treatment of advanced breast cancer patients in Canada. Patients receiving letrozole 2.5 mg have better clinical outcomes than megestrol acetate 160 mg patients and this increased benefit comes at a minimal and acceptable cost. In general the model proved insensitive to most of the uncertain variables, and was mainly sensitive to the efficacy parameters with second-line hormone therapy, which suggests that outcomes derived from this study should be judged cautiously.
This study was made possible by a grant from Novartis Pharma Canada, Inc. We are grateful for the participation of Liesbeth Meester, MSc in the study and for the following experts whose expertise in breast cancer treatment patterns assisted in the construction of a Canadaspecific model: Dr ME Blackstein, Mount Sinai Hospital, Toronto; Dr PHS Geggie, Tom Baker Cancer Center, Calgary; Dr KA Gelmon, BC Cancer Agency, Vancouver 
